Discovery of Novel GHB Ligands and Implications for Drug Research

Scientists in Copenhagen, Denmark, have made significant progress in understanding the mechanism of action of gamma-Hydroxybutyric acid (GHB), a proposed neurotransmitter or neuromodulator. Researchers at the University of Copenhagen have developed a novel compound, gamma-hydroxyfenbufen, which binds to GHB sites with 10-fold higher affinity than GHB itself. This breakthrough discovery has significant implications for drug research, particularly in the area of non-steroidal anti-inflammatory drugs (NSAIDs).

Key Takeaways:

• The researchers developed a novel compound, gamma-hydroxyfenbufen, which binds to GHB sites with 10-fold higher affinity than GHB.
• Gamma-hydroxyfenbufen was synthesized as the 4-hydroxyl analogue of the NSAID fenbufen.
• The active metabolite of fenbufen, 4-biphenylacetic acid, inhibited GHB binding with a twofold higher affinity than GHB.
• Diclofenac, a widely used over-the-counter drug, was identified as a GHB ligand with a K-i value of 5.1 μm.
• Other non-steroidal anti-inflammatory drugs (NSAIDs) of the phenylacetic acid (PAA) type also exhibited affinities similar to GHB.
• The identification of PAAs as GHB ligands provides new information about the structural preferences of the GHB ligand-binding site.
• The discovery of novel GHB ligands raises the interesting possibility that widely used drugs, such as diclofenac, may affect GHB binding at relevant clinical dosages.

Statistics:

• The affinity of gamma-hydroxyfenbufen for GHB sites is 10-fold higher than that of GHB (K-i 0.44 μM).
• The active metabolite of fenbufen, 4-biphenylacetic acid, inhibited GHB binding with a twofold higher affinity than GHB.
• Diclofenac has a K-i value of 5.1 μM for GHB binding.

Sources:

• Wellendorph, P., et al. (2009). Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain. Fundamental & Clinical Pharmacology, 23(2), 207-213.